Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders (2012 - 2026)

Dr Reddys Laboratories' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at $157.2 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 14.58% year-over-year to $157.2 million; the TTM figure through Mar 2026 stood at $458.7 million (down 31.35% YoY), while the FY2026 annual figure was $456.0 million, down 31.22% from the prior year.
• Net Income towards Common Stockholders was $157.2 million for Q1 2026 at Dr Reddys Laboratories, up from $135.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $184.1 million in Q1 2025 to a low of $152.0 in Q3 2022.
• Historically, Net Income towards Common Stockholders has averaged $147.8 million across 5 years, with a median of $161.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders sank 100.0% in 2022, then surged 117786349.35% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $116.8 million in 2022, then soared by 41.75% to $165.6 million in 2023, then grew by 1.08% to $167.4 million in 2024, then fell by 18.84% to $135.9 million in 2025, then climbed by 15.73% to $157.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $157.2 million (Q1 2026), $135.9 million (Q4 2025), and $165.7 million (Q2 2025), per Business Quant data.